About
Drug Repurposing
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (13)
Ambassador (Rtd) Howard Gutman
Algernon Pharmaceuticals
team_member
Christopher J. Moreau
Algernon Pharmaceuticals
team_member
Dr. Ahmad Khalil MD PhD
Medical Director
Algernon Pharmaceuticals
team_member
Dr. Andrew Maas, MD, PhD
Algernon Pharmaceuticals
team_member
Dr. Christopher Bryan, PhD
Vice President Research & Operations
Algernon Pharmaceuticals
executive
Dr. David L. Brody, MD, Ph.D.
Algernon Pharmaceuticals
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
248
By Phase
PHASE1: 1PHASE2/PHASE3: 1PHASE2: 1
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05559931Lead Sponsor
Single and Repeat Doses of DMT in Healthy Subjects
PHASE1Active, not recruiting
60 participants
Started: Jan 13, 2023 · Completed: Mar 31, 2026
NCT04382924Lead Sponsor
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
PHASE2/PHASE3Completed
168 participants
Started: Aug 5, 2020 · Completed: Jan 26, 2021
NCT04318704Lead Sponsor
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
PHASE2Completed
20 participants
Started: Jul 29, 2020 · Completed: May 10, 2022
Locations (1)
Headquarters
Vancouver, BC, Canada
Map
Loading map...